Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
J Virol ; 96(17): e0072322, 2022 09 14.
Article in English | MEDLINE | ID: mdl-35975999

ABSTRACT

The production of type I interferon (IFN) is the hallmark of the innate immune response. Most, if not all, mammalian viruses have a way to circumvent this response. Fundamental knowledge on viral evasion of innate immune responses may facilitate the design of novel antiviral therapies. To investigate how human metapneumovirus (HMPV) interacts with the innate immune response, recombinant viruses lacking G, short hydrophobic (SH), or M2-2 protein expression were assessed for IFN induction in A549 cells. HMPV lacking G or SH protein expression induced similarly low levels of IFN, compared to the wild-type virus, whereas HMPV lacking M2-2 expression induced significantly more IFN than the wild-type virus. However, sequence analysis of the genomes of M2-2 mutant viruses revealed large numbers of mutations throughout the genome. Over 70% of these nucleotide substitutions were A-to-G and T-to-C mutations, consistent with the properties of the adenosine deaminase acting on RNA (ADAR) protein family. Knockdown of ADAR1 by CRISPR interference confirmed the role of ADAR1 in the editing of M2-2 deletion mutant virus genomes. More importantly, Northern blot analyses revealed the presence of defective interfering RNAs (DIs) in M2-2 mutant viruses and not in the wild-type virus or G and SH deletion mutant viruses. DIs are known to be potent inducers of the IFN response. The presence of DIs in M2-2 mutant virus stocks and hypermutated virus genomes interfere with studies on HMPV and the innate immune response and should be addressed in future studies. IMPORTANCE Understanding the interaction between viruses and the innate immune response is one of the barriers to the design of antiviral therapies. Here, we investigated the role of the G, SH, and M2-2 proteins of HMPV as type I IFN antagonists. In contrast to other studies, no IFN-antagonistic functions could be observed for the G and SH proteins. HMPV with a deletion of the M2-2 protein did induce type I IFN production upon infection of airway epithelial cells. However, during generation of virus stocks, these viruses rapidly accumulated DIs, which are strong activators of the type I IFN response. Additionally, the genomes of these viruses were hypermutated, which was prevented by generating stocks in ADAR knockdown cells, confirming a role for ADAR in hypermutation of HMPV genomes or DIs. These data indicate that a role of the HMPV M2-2 protein as a bona fide IFN antagonist remains elusive.


Subject(s)
Immunity, Innate , Interferon Type I , Metapneumovirus , Viral Proteins , A549 Cells , Adenosine Deaminase , Antiviral Agents/metabolism , Humans , Interferon Type I/antagonists & inhibitors , Interferon Type I/immunology , Metapneumovirus/genetics , Metapneumovirus/metabolism , RNA-Binding Proteins , Viral Proteins/genetics , Viral Proteins/metabolism
2.
Vet Microbiol ; 269: 109437, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35472508

ABSTRACT

Newcastle Disease virus (NDV) has shown promise as an oncolytic virus for treatment of a wide range of tumours. NDV with a multi-basic cleavage site (MBCS) in the fusion (F) protein (NDV F3aa) has increased oncolytic efficacy in several tumour models, but also increased virulence in chickens compared to non-virulent NDV F0, raising potential environmental safety issues. Previously, we generated a variant of NDV F3aa with a disrupted V protein gene and a substitution of phenylalanine to serine at position 117 of the F protein (NDV F3aa-S-STOPV). Compared to NDV F3aa this virus had decreased virulence in embryonated chicken eggs. In this study, the virulence of the virus was evaluated upon inoculation of six-week-old chickens through a natural infection route and by determination of the intracerebral pathogenicity index (ICPI). Based on these data NDV F3aa-S-STOPV classified as a non-virulent virus. Although NDV F3aa was classified as a virulent virus based on the ICPI, the virus was also less pathogenic than NDV F0 upon inoculation of six-week-old chickens. These data indicate that NDV with a MBCS is not necessarily pathogenic in chickens. In addition, these data show that F3aa-S-STOPV is safe to use in viro-immunotherapies without posing a threat for chickens upon accidental exposure.


Subject(s)
Newcastle Disease , Poultry Diseases , Animals , Chickens , Newcastle disease virus/genetics , Viral Fusion Proteins/genetics , Viral Fusion Proteins/metabolism , Virulence/genetics
3.
Cytokine Growth Factor Rev ; 56: 124-132, 2020 12.
Article in English | MEDLINE | ID: mdl-32919831

ABSTRACT

Oncolytic virus immunotherapy is rapidly gaining interest in the field of immunotherapy against cancer. The minimal toxicity upon treatment and the dual activity of direct oncolysis and immune activation make therapy with oncolytic viruses (OVs) an interesting treatment modality. The safety and efficacy of several OVs have been assessed in clinical trials and, so far, the Food and Drug Administration (FDA) has approved one OV. Unfortunately, most treatments with OVs have shown suboptimal responses in clinical trials, while they appeared more promising in preclinical studies, with tumours reducing after immune cell influx. In several clinical trials with OVs, parameters such as virus replication, virus-specific antibodies, systemic immune responses, immune cell influx into tumours and tumour-specific antibodies have been studied as predictors or correlates of therapy efficacy. In this review, these studies are summarized to improve our understanding of the determinants of the efficacy of OV therapies in humans and to provide insights for future developments in the viro-immunotherapy treatment field.


Subject(s)
Immunotherapy , Neoplasms , Oncolytic Virotherapy , Oncolytic Viruses , Humans , Neoplasms/therapy , Virus Replication
4.
J Virol ; 93(6)2019 03 15.
Article in English | MEDLINE | ID: mdl-30567988

ABSTRACT

The acute antiviral response is mediated by a family of interferon-stimulated genes (ISGs), providing cell-intrinsic immunity. Mutations in genes encoding these proteins are often associated with increased susceptibility to viral infections. One family of ISGs with antiviral function is the interferon-inducible transmembrane proteins (IFITMs), of which IFITM3 has been studied extensively. In contrast, IFITM1 has not been studied in detail. Since IFITM1 can localize to the plasma membrane, we investigated its function with a range of enveloped viruses thought to infect cells by fusion with the plasma membrane. Overexpression of IFITM1 prevented infection by a number of Paramyxoviridae and Pneumoviridae, including respiratory syncytial virus (RSV), mumps virus, and human metapneumovirus (HMPV). IFITM1 also restricted infection with an enveloped DNA virus that can enter via the plasma membrane, herpes simplex virus 1 (HSV-1). To test the importance of plasma membrane localization for IFITM1 function, we identified blocks of amino acids in the conserved intracellular loop (CIL) domain that altered the subcellular localization of the protein and reduced antiviral activity. By screening reported data sets, 12 rare nonsynonymous single nucleotide polymorphisms (SNPs) were identified in human IFITM1, some of which are in the CIL domain. Using an Ifitm1-/- mouse, we show that RSV infection was more severe, thereby extending the range of viruses restricted in vivo by IFITM proteins and suggesting overall that IFITM1 is broadly antiviral and that this antiviral function is associated with cell surface localization.IMPORTANCE Host susceptibility to viral infection is multifactorial, but early control of viruses not previously encountered is predominantly mediated by the interferon-stimulated gene (ISG) family. There are upwards of 300 of these genes, the majority of which do not have a clearly defined function or mechanism of action. The cellular location of these proteins may have an important effect on their function. One ISG located at the plasma membrane is interferon-inducible transmembrane protein 1 (IFITM1). Here we demonstrate that IFITM1 can inhibit infection with a range of viruses that enter via the plasma membrane. Mutant IFITM1 proteins that were unable to localize to the plasma membrane did not restrict viral infection. We also observed for the first time that IFITM1 plays a role in vivo, and Ifitm1-/- mice were more susceptible to viral lung infection. These data contribute to our understanding of how ISGs prevent viral infections.


Subject(s)
Antigens, Differentiation/metabolism , Cell Membrane/virology , Paramyxoviridae/drug effects , Pneumovirinae/drug effects , Virus Internalization/drug effects , Virus Replication/drug effects , A549 Cells , Amino Acid Sequence , Animals , Cell Line , Cell Line, Tumor , Chlorocebus aethiops , HEK293 Cells , Humans , Interferons/pharmacology , Membrane Proteins/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Polymorphism, Single Nucleotide/drug effects , Vero Cells
5.
Cytokine Growth Factor Rev ; 41: 28-39, 2018 06.
Article in English | MEDLINE | ID: mdl-29576283

ABSTRACT

Oncolytic viruses (OVs), viruses that specifically result in killing tumor cells, represent a promising class of cancer therapy. Recently, the focus in the OV therapy field has shifted from their direct oncolytic effect to their immune stimulatory effect. OV therapy can function as a "kick start" for the antitumor immune response by releasing tumor associated antigens and release of inflammatory signals. Combining OVs with immune modulators could enhance the efficacy of both immune and OV therapies. Additionally, genetic engineering of OVs allows local expression of immune therapeutics, thereby reducing related toxicities. Different options to modify the tumor microenvironment in combination with OV therapy have been explored. The possibilities and obstacles of these combinations will be discussed in this review.


Subject(s)
Antineoplastic Agents/immunology , Neoplasms/immunology , Neoplasms/therapy , Oncolytic Viruses/immunology , Animals , Humans , Immunologic Factors/immunology , Tumor Microenvironment/immunology
6.
Methods Mol Biol ; 1602: 125-139, 2017.
Article in English | MEDLINE | ID: mdl-28508218

ABSTRACT

Human metapneumovirus (HMPV), a single-stranded negative-sense RNA virus belonging to the family Paramyxoviridae, is associated with respiratory tract illness, primarily in young children and persons with underlying disease. Based on genetic and antigenic variation, HMPV strains are classified into two serotypes, with isolates NL/1/00 and NL/1/99 as prototypes for serotypes A and B, respectively. The development of plasmid-based reverse genetics systems for both serotypes has resulted in developments of a wide range of vaccine candidates against HMPV infection. The approach to virus rescue of HMPV is similar to that used for other paramyxoviruses, starting with mini-replicon assays for optimizations of the rescue protocols and subsequent replacement of the mini genome with a plasmid expressing the cDNA of the full-length viral RNA genome. Here, we provide detailed information on the reverse genetics systems for HMPV.


Subject(s)
DNA, Complementary , Metapneumovirus/genetics , Metapneumovirus/isolation & purification , RNA, Viral , Virus Replication , Animals , Cell Line , Gene Expression , Genes, Reporter , Genetic Vectors , Genome, Viral , Humans , Plasmids/genetics , Reassortant Viruses/genetics , Recombination, Genetic , Reverse Genetics , Virion/genetics , Virion/growth & development , Virion/isolation & purification
7.
Antimicrob Agents Chemother ; 60(8): 4620-9, 2016 08.
Article in English | MEDLINE | ID: mdl-27185803

ABSTRACT

The clinical impact of infections with respiratory viruses belonging to the family Paramyxoviridae argues for the development of antiviral therapies with broad-spectrum activity. Favipiravir (T-705) has demonstrated potent antiviral activity against multiple RNA virus families and is presently in clinical evaluation for the treatment of influenza. Here we demonstrate in vitro activity of T-705 against the paramyxoviruses human metapneumovirus (HMPV), respiratory syncytial virus, human parainfluenza virus, measles virus, Newcastle disease virus, and avian metapneumovirus. In addition, we demonstrate activity against HMPV in hamsters. T-705 treatment inhibited replication of all paramyxoviruses tested in vitro, with 90% effective concentration (EC90) values of 8 to 40 µM. Treatment of HMPV-challenged hamsters with T-705 at 200 mg/kg of body weight/day resulted in 100% protection from infection of the lungs. In all treated and challenged animals, viral RNA remained detectable in the respiratory tract. The observation that T-705 treatment had a significant effect on infectious viral titers, with a limited effect on viral genome titers, is in agreement with its proposed mode of action of viral mutagenesis. However, next-generation sequencing of viral genomes isolated from treated and challenged hamsters did not reveal (hyper)mutation. Polymerase activity assays revealed a specific effect of T-705 on the activity of the HMPV polymerase. With the reported antiviral activity of T-705 against a broad range of RNA virus families, this small molecule is a promising broad-range antiviral drug candidate for limiting the viral burden of paramyxoviruses and for evaluation for treatment of infections with (re)emerging viruses, such as the henipaviruses.


Subject(s)
Amides/pharmacology , Antiviral Agents/pharmacology , Metapneumovirus/drug effects , Paramyxoviridae Infections/drug therapy , Pyrazines/pharmacology , Animals , Antibodies, Viral/immunology , Chlorocebus aethiops , Cricetinae , HEK293 Cells , Humans , Lung/virology , Mesocricetus , Respiratory Syncytial Viruses/drug effects , Vero Cells , Virus Replication/drug effects
8.
Gene Ther ; 22(12): 947-59, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26196249

ABSTRACT

Oncolytic viruses (OV) have broad potential as an adjuvant for the treatment of solid tumors. The present study addresses the feasibility of clinically applicable drugs to enhance the oncolytic potential of the OV Delta24-RGD in glioblastoma. In total, 446 drugs were screened for their viral sensitizing properties in glioblastoma stem-like cells (GSCs) in vitro. Validation was done for 10 drugs to determine synergy based on the Chou Talalay assay. Mechanistic studies were undertaken to assess viability, replication efficacy, viral infection enhancement and cell death pathway induction in a selected panel of drugs. Four viral sensitizers (fluphenazine, indirubin, lofepramine and ranolazine) were demonstrated to reproducibly synergize with Delta24-RGD in multiple assays. After validation, we underscored general applicability by testing candidate drugs in a broader context of a panel of different GSCs, various solid tumor models and multiple OVs. Overall, this study identified four viral sensitizers, which synergize with Delta24-RGD and two other strains of OVs. The viral sensitizers interact with infection, replication and cell death pathways to enhance efficacy of the OV.


Subject(s)
Glioblastoma/therapy , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/virology , Oncolytic Virotherapy/methods , Oncolytic Viruses/drug effects , Brain Neoplasms/drug therapy , Brain Neoplasms/therapy , Brain Neoplasms/virology , Cell Line, Tumor , Drug Evaluation, Preclinical , Fluphenazine/pharmacology , Glioblastoma/drug therapy , Glioblastoma/virology , HCT116 Cells , Humans , Indoles/pharmacology , Oncolytic Viruses/physiology , Virus Replication/drug effects
9.
Cancer Gene Ther ; 21(11): 463-71, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25257305

ABSTRACT

Newcastle disease virus (NDV) is an avian paramyxovirus with oncolytic potential. Detailed preclinical information regarding the safety of oncolytic NDV is scarce. In this study, we evaluated the toxicity, biodistribution and shedding of intravenously injected oncolytic NDVs in non-human primates (Macaca fascicularis). Two animals were injected with escalating doses of a non-recombinant vaccine strain, a recombinant lentogenic strain or a recombinant mesogenic strain. To study transmission, naive animals were co-housed with the injected animals. Injection with NDV did not lead to severe illness in the animals or abnormalities in hematologic or biochemistry measurements. Injected animals shed low amounts of virus, but this did not lead to seroconversion of the contact animals. Postmortem evaluation demonstrated no pathological changes or evidence of virus replication. This study demonstrates that NDV generated in embryonated chicken eggs is safe for intravenous administration to non-human primates. In addition, our study confirmed results from a previous report that naïve primate and human sera are able to neutralize egg-generated NDV. We discuss the implications of these results for our study and the use of NDV for virotherapy.


Subject(s)
Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/toxicity , Newcastle disease virus/genetics , Oncolytic Virotherapy/methods , Allantois/virology , Animals , Antineoplastic Agents/administration & dosage , Cell Line , Chick Embryo , DNA, Complementary/genetics , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Injections, Intravenous , Macaca fascicularis , Male , Mutagenesis, Site-Directed , Neutralization Tests , Reverse Transcriptase Polymerase Chain Reaction , Viral Vaccines/administration & dosage , Virus Shedding
10.
Cancer Gene Ther ; 21(1): 24-30, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24384773

ABSTRACT

Newcastle disease virus (NDV) is a naturally occurring oncolytic virus with clinically proven efficacy against several human tumor types. Selective replication in and killing of tumor cells by NDV is thought to occur because of differences in innate immune responses between normal and tumor cells. In our effort to develop oncolytic virotherapy with NDV for patients with pancreatic cancer, we evaluated the responses to NDV infection and interferon (IFN) treatment of 11 different established human pancreatic adenocarcinoma cell lines (HPACs). Here we show that all HPACs were susceptible to NDV. However, this NDV infection resulted in different replication kinetics and cytotoxic effects. Better replication resulted in more cytotoxicity. No correlation was observed between defects in the IFN pathways and NDV replication or NDV-induced cytotoxicity. IFN production by HPACs after NDV infection differed substantially. Pretreatment of HPACs with IFN resulted in diminished NDV replication and decreased the cytotoxic effects in most HPACs. These findings suggest that not all HPACs have functional defects in the innate immune pathways, possibly resulting in resistance to oncolytic virus treatment. These data support the rationale for designing recombinant oncolytic NDVs with optimized virulence that should likely contain an antagonist of the IFN pathways.


Subject(s)
Adenocarcinoma/immunology , Genetic Vectors/immunology , Newcastle disease virus/immunology , Oncolytic Viruses/immunology , Pancreatic Neoplasms/immunology , Adenocarcinoma/therapy , Cell Line, Tumor , Cytopathogenic Effect, Viral , Humans , Immunity, Innate , Interferon-beta/biosynthesis , Interferon-beta/pharmacology , Interferons/biosynthesis , Newcastle disease virus/drug effects , Oncolytic Virotherapy , Oncolytic Viruses/drug effects , Pancreatic Neoplasms/therapy , Signal Transduction , Virus Replication/drug effects
11.
Clin Microbiol Infect ; 17(12): 1840-4, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21883660

ABSTRACT

It remains largely unknown which factors determine the clinical outcome of human metapneumovirus (HMPV) infections. The aim of the present study was to analyse whether exposure to bacterial pathogens can influence HMPV infections. From 57 children, serum samples and colonization data for Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus and Streptococcus pneumoniae were collected at 1.5, 6, 14 and 24 months of age. Seroconversion rates to HMPV were determined and related to bacterial carriage. Frequent nasopharyngeal carriage (≥2 times in the first 2 years of life) of S. pneumoniae, but not of the other three pathogens, was associated with increased seroconversion rates of infants to HMPV at the age of 2 years (frequently vs. less exposed, 93% vs. 59%; p <0.05). Subsequently, the susceptibility of well-differentiated normal human bronchial epithelial cells (wd-NHBE) pre-incubated with bacterial pathogens to in vitro HMPV infection was evaluated. Pre-incubation of wd-NHBE with S. pneumoniae resulted in increased susceptibility to infection with HMPV-enhanced green fluorescent protein (EGFP), as determined by enumeration of EGFP-positive cells. This was not the case for cells pre-incubated with H. influenzae, M. catarrhalis on S. aureus. We conclude that exposure to S. pneumoniae can modulate HMPV infection.


Subject(s)
Antibodies, Viral/blood , Carrier State , Disease Susceptibility , Metapneumovirus/isolation & purification , Paramyxoviridae Infections/epidemiology , Pneumococcal Infections/complications , Streptococcus pneumoniae/pathogenicity , Child, Preschool , Haemophilus influenzae/isolation & purification , Haemophilus influenzae/pathogenicity , Humans , Infant , Metapneumovirus/immunology , Moraxella catarrhalis/isolation & purification , Moraxella catarrhalis/pathogenicity , Nasopharynx/microbiology , Paramyxoviridae Infections/immunology , Paramyxoviridae Infections/virology , Staphylococcus aureus/isolation & purification , Staphylococcus aureus/pathogenicity , Streptococcus pneumoniae/isolation & purification
12.
Bone Marrow Transplant ; 31(4): 309-10, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12621469

ABSTRACT

Respiratory viruses are increasingly recognized as a cause of pneumonitis following haematopoietic stem cell transplantation (HSCT). However, frequently, no pathogen is identified in cases of suspected viral pneumonia. Recently, a previously undescribed paramyxovirus, designated 'human metapneumovirus' (hMPV), was isolated from children with respiratory illness. We have detected hMPV as the sole pathogen in the nasopharyngeal aspirate of an HSCT recipient who succumbed to progressive respiratory failure following an upper respiratory prodrome. This report highlights the importance of further studies to elucidate the role of hMPV in causing respiratory illnesses in the HSCT population.


Subject(s)
Metapneumovirus , Paramyxoviridae Infections/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Stem Cell Transplantation/adverse effects , Adult , Fatal Outcome , Female , Histocompatibility Testing , Humans , Lymphocyte Depletion , Metapneumovirus/isolation & purification , Paramyxoviridae Infections/diagnosis , Respiratory Insufficiency/etiology , Respiratory Insufficiency/virology , Transplantation, Homologous
13.
Nat Med ; 7(6): 719-24, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11385510

ABSTRACT

From 28 young children in the Netherlands, we isolated a paramyxovirus that was identified as a tentative new member of the Metapneumovirus genus based on virological data, sequence homology and gene constellation. Previously, avian pneumovirus was the sole member of this recently assigned genus, hence the provisional name for the newly discovered virus: human metapneumovirus. The clinical symptoms of the children from whom the virus was isolated were similar to those caused by human respiratory syncytial virus infection, ranging from upper respiratory tract disease to severe bronchiolitis and pneumonia. Serological studies showed that by the age of five years, virtually all children in the Netherlands have been exposed to human metapneumovirus and that the virus has been circulating in humans for at least 50 years.


Subject(s)
Paramyxoviridae Infections/virology , Paramyxoviridae/genetics , Paramyxoviridae/isolation & purification , Respiratory Tract Infections/virology , Adolescent , Adult , Aged , Aged, 80 and over , Amino Acid Sequence , Animals , Base Sequence , Chickens , Child , Child, Preschool , Female , Genome, Viral , Humans , Infant , Infant, Newborn , Macaca fascicularis , Male , Middle Aged , Molecular Sequence Data , Netherlands/epidemiology , Paramyxoviridae/classification , Paramyxoviridae/ultrastructure , Paramyxoviridae Infections/epidemiology , Phylogeny , Polymerase Chain Reaction/methods , Respiratory Tract Infections/epidemiology , Seroepidemiologic Studies , Turkeys , Viral Proteins/chemistry , Viral Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...